UniQuest is the commercialisation company ofThe University of Queensland

In partnership with UQ researchers, we create impact through the commercialisation of UQ intellectual property (IP).  Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia.

UQ leads Australia’s Group of Eight universities in commercialisation revenue received, the number of active start-ups and the value of equity held in start-ups formed from university IP*.

Notable successes include the blockbuster cervical cancer vaccine Gardasil® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-up exits in Australian history.

UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI), a world-class small molecule drug discovery and development group, dedicated to translating academic biomedical research into drug candidates for partnering.

*2021 Survey of Commercialisation Outcomes from Public Research (SCOPR)

Our Purpose

Through commercialisation of intellectual property, in partnership with UQ researchers, we create societal and economic impact.

Our Values


Respectful of the views of others and open to change.

Act with integrity

Manage conflict of interest, accountable and professional.


Value our people, consultative and communicate effectively.


Honest, reliable and empowered.

Commercial excellence

Financially astute with timely and disciplined decision-making.

Memorandum of Understanding

In 2022 a Memorandum of Understanding (MoU) was signed to support continued strategic alignment between UniQuest and The University of Queensland.

Download the MoU